PT-141 Guide
Bremelanotide: The Brain-Based Sexual Health Peptide
PT-141 (bremelanotide) is a synthetic melanocortin peptide that works through the brain — not blood vessels. FDA-approved as Vyleesi for hypoactive sexual desire disorder in women, it is the first non-hormonal drug approved for female sexual dysfunction and shows significant results in men who don't respond to Viagra.
What Is PT-141?
PT-141, chemically known as bremelanotide, is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It was originally derived from Melanotan II — a compound investigated for tanning — when researchers noticed its potent effects on sexual arousal as an unintended finding. PT-141 retained the sexual arousal activity while the tanning properties were largely removed in its structural design.
The FDA approved bremelanotide in 2019 as Vyleesi (1.75mg subcutaneous auto-injector) for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it the first and only non-hormonal drug approved specifically for female sexual dysfunction acting through the central nervous system. Unlike estrogen-based treatments that address lubrication or vaginal atrophy, Vyleesi addresses the neurological origin of low desire.
In the research community, PT-141 is used at doses lower than the FDA-approved 1.75mg (typically 0.5–1mg) primarily to reduce the most common side effect: nausea. Both the research form (lyophilized powder for reconstitution) and the branded Vyleesi auto-injector contain the same active molecule.
Vyleesi (bremelanotide 1.75mg) — first non-hormonal CNS drug approved for HSDD in premenopausal women.
Acts on melanocortin receptors 3 and 4 in the hypothalamus — the brain regions governing sexual motivation and dopamine release.
Inject 45–90 minutes before activity. Half-life of 2–3 hours. On-demand use — not daily dosing.
How PT-141 Works: CNS vs. Blood Flow
Melanocortin Receptor Activation
PT-141 activates MC3R and MC4R receptors concentrated in the hypothalamus — particularly in the medial preoptic area (MPOA), the brain's primary sexual motivation center. This activation triggers downstream dopamine release in mesolimbic pathways (the brain's reward circuit), increasing sexual desire at the neurological level before any peripheral physical response occurs.
This is fundamentally different from any sexual dysfunction drug previously approved — all prior options either manipulated hormones or worked on genital blood flow. PT-141 is the first to directly target the brain circuits governing desire and motivation.
PT-141 vs. PDE5 Inhibitors (Viagra/Cialis)
Sildenafil (Viagra) and tadalafil (Cialis) inhibit PDE5 enzyme in penile smooth muscle, preventing cGMP breakdown and maintaining vasodilation — increasing blood flow to erectile tissue. They require sexual stimulation to work and have no effect on desire itself. They do not cross the blood-brain barrier in meaningful concentrations.
PT-141 acts upstream — on desire and motivation — and can produce erections in men through CNS pathways independently of peripheral blood flow mechanisms. This is why PT-141 can work in men with erectile dysfunction who have failed PDE5 inhibitors: the failure point was not desire or CNS signaling, but the two mechanisms address different aspects of sexual response and can be combined.
Women: HSDD Mechanism
In women with HSDD, the problem is neurological — reduced central dopaminergic tone in sexual motivation pathways, often compounded by increased serotonergic inhibition. PT-141's MC4R activation increases dopamine in these circuits, addressing the neurological root cause rather than peripheral lubrication or hormonal levels. Clinical trials showed significantly reduced distress from low desire in premenopausal women — the FDA-approved endpoint.
Importantly, PT-141 does not affect estrogen or other hormones — making it suitable for women who cannot use hormonal treatments (e.g., breast cancer survivors on aromatase inhibitors).
Men: Off-Label Sexual Function
PT-141 is not FDA-approved for male sexual dysfunction but is extensively studied and used in research settings. Published studies demonstrate significant improvements in erectile function scores, including in men classified as poor responders to sildenafil. One Phase 2 trial showed over 80% of men treated with intranasal PT-141 experienced clinically meaningful improvement.
The subcutaneous form is generally preferred over intranasal in research contexts due to more reliable bioavailability. Men using PT-141 commonly report not only erectile quality improvements but also increased libido and subjective arousal — effects that PDE5 inhibitors do not produce.
PT-141 Dosage & Protocol
PT-141 is an on-demand peptide — it is not taken daily or on a cycle in the traditional sense. It is injected subcutaneously (typically in the abdomen or thigh) approximately 45–90 minutes before sexual activity, allowing sufficient time for the CNS onset to occur. The half-life of approximately 2–3 hours means effects are present for the window of activity before declining.
FDA-Approved Dose (Vyleesi)
- • Dose: 1.75mg subcutaneous
- • Timing: 45 minutes before activity
- • Auto-injector: pre-filled pen
- • Max frequency: once per 24 hours
- • Not for daily use — on-demand only
- • Indication: HSDD in premenopausal women
Research Community Protocol
- • Dose: 0.5–1mg subcutaneous
- • Timing: 60–90 minutes before activity
- • Lower dose reduces nausea significantly
- • Reconstituted from lyophilized powder
- • Men typically use 1mg starting dose
- • Women often find 0.5mg sufficient
Side Effects & Safety
Common Side Effects
- Nausea (most common): Dose-dependent — occurs in approximately 40% of users at 1.75mg, significantly less at 0.5–1mg. Usually mild to moderate, resolves within 1–2 hours. Taking with a light meal or ginger can reduce severity.
- Flushing: Warmth or redness, typically facial, from melanocortin receptor activity. Transient, usually 15–30 minutes.
- Transient blood pressure increase: Modest elevation that typically resolves within 12 hours. Clinically significant in susceptible individuals. Monitor if cardiovascular risk factors are present.
- Hyperpigmentation: With repeated frequent use — MC1R activity can cause focal skin darkening. Less common at low doses and infrequent use.
Safety & Contraindications
- Do NOT combine with alkyl nitrates: Same contraindication as PDE5 inhibitors — combined vasodilatory effect can cause severe hypotension. This includes poppers (amyl/butyl nitrate) used recreationally.
- Cardiovascular risk: The transient blood pressure elevation means PT-141 should be used with caution in patients with uncontrolled hypertension or significant cardiovascular disease.
- No hormonal interactions: Does not affect estrogen, testosterone, or other hormonal axes — a key advantage for patients on hormone-sensitive treatments.
- Pregnancy: Contraindicated during pregnancy. Not studied in breastfeeding.
PT-141 in Context: Comparisons
PT-141 and Vyleesi contain the same active molecule (bremelanotide). The Vyleesi auto-injector is the branded, FDA-approved version at the approved 1.75mg dose. Research-grade PT-141 is the lyophilized powder form that researchers and off-label users reconstitute, typically at lower doses to manage nausea.
PT-141 vs. Kisspeptin
Kisspeptin is a neuropeptide that activates the HPG (hypothalamic-pituitary-gonadal) axis, primarily studied for fertility and reproductive hormone regulation. It has secondary effects on sexual behavior through gonadotropin release. PT-141 acts directly on melanocortin receptors for immediate desire effects — kisspeptin acts more upstream, affecting the hormonal axis over a longer timeframe. They target different aspects of sexual function and are not direct competitors.
PT-141 vs. Flibanserin (Addyi)
Flibanserin (Addyi) is a daily oral pill for HSDD acting on serotonin and dopamine receptors. It has modest efficacy and severe interactions with alcohol (dangerous hypotension). PT-141 is used on-demand with no alcohol interaction concern, produces more consistent subjective results in clinical data, and has a cleaner side effect profile at lower doses. The on-demand nature of PT-141 is considered a significant practical advantage.
Frequently Asked Questions
What is PT-141 and how does it work?
PT-141 (bremelanotide) is a synthetic melanocortin peptide derived from Melanotan II. It activates MC3R and MC4R receptors in the brain's hypothalamus to increase sexual motivation through dopaminergic pathways. Unlike Viagra or Cialis, which act on peripheral blood flow, PT-141 works centrally on the brain circuits governing desire and arousal. It is FDA-approved as Vyleesi (1.75mg subcutaneous) for hypoactive sexual desire disorder in premenopausal women.
What is the recommended PT-141 dosage and when should I inject it?
The FDA-approved Vyleesi dose is 1.75mg subcutaneously 45 minutes before sexual activity. The research community commonly uses 0.5–1mg to significantly reduce nausea — the most common side effect at higher doses. Onset takes 45–90 minutes and the half-life is 2–3 hours. PT-141 is an on-demand peptide, not intended for daily use.
Does PT-141 work for men, and is it different from Viagra?
Yes. PT-141 has been studied in men and shows significant erection quality improvements, including in men who do not respond to PDE5 inhibitors. Viagra acts peripherally on blood flow; PT-141 acts centrally on brain desire circuits — they address different aspects of sexual response and are complementary. PT-141 is not FDA-approved for male sexual dysfunction but is widely used off-label.
Track Your PT-141 Protocol with Shotlee
Log every dose, timing, and response — so you have real data on what your protocol is doing and when it works best for you.
Start Tracking Free